MGNX Projected Dividend Yield
MacroGenics, Inc ( NASDAQ : MGNX )MacroGenics is a biopharmaceutical company. Co.'s main pipeline program is vobramitamab duocarmazine, an antibody-drug conjugate that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Co. is also developing molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. In addition, Co. is developing MGD024, a bispecific DART molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia. 20 YEAR PERFORMANCE RESULTS |
MGNX Dividend History Detail MGNX Dividend News MGNX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |